PENMENVY helps protect against ALL 5 vaccine-preventable serogroups of meningitis: A, B, C, W, and Y

PENMENVY combines components of two vaccines that are FDA approved to help protect teens and young adults from meningococcal disease (also known as meningitis).

Vaccination may not protect all recipients.

Why choose PENMENVY?

Logos for PENMENVY, BEXSERO, and MENVEO

ONE pentavalent vaccine for meningitis protection built from components of TWO FDA-approved vaccines (MENVEO and BEXSERO).

 

PENMENVY is a vaccine approved in 10- through 25-year-olds to prevent invasive meningococcal disease (also known as meningitis) caused by Neisseria meningitidis serogroups A, B, C, W, and Y. PENMENVY is administered as an injection into the muscle.

 

Help protect your teen against ALL 5 vaccine-preventable meningitis groups—A, B, C, W, and Y—with PENMENVY. Talk to your teen’s healthcare professional today.

Teen and her mother talking to a doctor

Who should receive the PENMENVY meningitis vaccine?

Adolescents and young adults ages 16-23 are at increased risk for meningitis, an uncommon but serious disease. Your teen may be missing vaccination against certain meningitis groups even if they’ve been vaccinated in the past.

 

There are separate vaccinations available for meningococcal groups A, C, W, and Y (MenACWY) and group B (MenB). The Centers for Disease Control and Prevention (CDC) recommends routine MenACWY vaccination at age 11–12 years and a booster dose at age 16 years. Most teens received MenACWY vaccination at age 11 or 12 but may still be missing the booster dose recommended at age 16.

 

In addition, millions of teens are still missing vaccination for meningitis B. The decision to vaccinate against meningitis B is based on a conversation with your teen’s doctor starting when your child turns 16 years old. The CDC recommends the MenB vaccine series may be given to adolescents and young adults age 16-23 years (preferred age 16-18 years) not at increased risk for meningitis as 2 doses, 6 months apart.*

 

One benefit of PENMENVY is that it helps protect against ALL 5 vaccine-preventable meningitis groups with one less shot.† The CDC recommends MenABCWY vaccination as an option if someone is receiving MenACWY and MenB vaccines at the same visit.‡

 

*MenB series may require more than 2 doses.

†Compared to separately administered meningococcal groups A, C, W, Y and group B vaccines.

‡FDA-approved Prescribing Information for MENVEO and BEXSERO does not include information on getting MENVEO and BEXSERO at the same visit.

Help protect your teen against ALL 5 vaccine-preventable meningitis groups—A, B, C, W, and Y. Call your teen’s doctor today.

Approved Uses and Important Safety Information for PENMENVY, BEXSERO, and MENVEO

What are PENMENVY, BEXSERO, and MENVEO?

Important Safety Information About PENMENVY, BEXSERO, and MENVEO

What are PENMENVY, BEXSERO, and MENVEO?

PENMENVY is an FDA-approved vaccine to prevent invasive disease caused by Neisseria meningitidis serogroups A, B, C, W, and Y in individuals 10 through 25 years of age.

 

BEXSERO is an FDA-approved vaccine to prevent invasive disease caused by N. meningitidis serogroup B. BEXSERO is approved for use in individuals aged 10 through 25 years.

 

MENVEO is an FDA-approved vaccine to prevent invasive disease caused by N. meningitidis serogroups A, C, W, and Y. MENVEO does not prevent disease caused by serogroup B infections. MENVEO is approved for use in individuals 2 months through 55 years of age.  

Important Safety Information About PENMENVY, BEXSERO, and MENVEO

  • Anyone who had a severe allergic reaction to a previous dose of PENMENVY, to one of its ingredients, or to any other diphtheria toxoid-containing vaccine should not receive PENMENVY
  • Anyone who had a severe allergic reaction to a previous dose of MENVEO, to one of its ingredients, or to any other diphtheria toxoid-containing vaccine should not receive MENVEO
  • Anyone who is allergic to the ingredients of BEXSERO or who had a severe allergic reaction after a previous dose should not receive BEXSERO
  • For BEXSERO, the tip cap of the prefilled syringe may or may not be made with natural rubber latex. Natural rubber latex may cause allergic reactions
  • Fainting can happen after getting PENMENVY, BEXSERO, or MENVEO. Precautions should be taken to avoid injury due to fainting
  • PENMENVY, BEXSERO, or MENVEO may not protect all vaccine recipients
  • Some individuals with weakened immune systems, including those receiving immunosuppressive treatment, may have reduced immune responses to PENMENVY, BEXSERO, or MENVEO
  • Individuals with certain complement deficiencies and individuals receiving treatment that inhibits complement function are at increased risk for invasive disease caused by N. meningitidis, including disease caused by groups A, B, C, W, and Y, even after being vaccinated with PENMENVY, BEXSERO, or MENVEO
  • Guillain-Barré syndrome (GBS) has been reported following administration of another US-licensed meningococcal vaccine for groups A, C, W, and Y. Ask your healthcare provider about the risks and benefits of PENMENVY or MENVEO if you have a history of GBS
  • For PENMENVY, the most common side effects are pain, redness, and swelling at the injection site; fatigue; headache; muscle pain; and nausea
  • For BEXSERO, the most common side effects are pain, redness or swelling at the injection site; fatigue; headache; nausea; and muscle pain
  • For MENVEO, the most common side effects among adolescents and adults aged 11 through 55 years who received a single dose of MENVEO were pain at the injection site; headache; muscle pain; malaise; and nausea. Across all age groups, some events were severe. Similar side effects among adolescents and adults occurred following a single booster dose
  • Tell your healthcare provider if you are pregnant, plan to become pregnant, or are breast-feeding
  • Ask your healthcare provider about the risks and benefits of PENMENVY, BEXSERO, and MENVEO. Only a healthcare provider can decide if PENMENVY, BEXSERO, and MENVEO are right for you or your child

 

Prescribing Information for PENMENVY (Meningococcal Groups A, B, C, W, and Y Vaccine)

 

Prescribing Information for BEXSERO (Meningococcal Group B Vaccine)

 

Prescribing Information for MENVEO [Meningococcal (Groups A, C, Y and W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine]

You are encouraged to report vaccine adverse events to the US Department of Health and Human Services.
Visit www.vaers.hhs.gov to file a report or call 1-800-822-7967. You may also file a report with GSK at gsk.public.reportum.com or 1-888-825-5249.
GSK Help Center logo

Explore the GSK Help Center website to find customer service support and contact information.

Contact Us
GSK For You logo

If you have questions about how to access your GSK medication or need cost information, visit gskforyou.com or call 1-866-GSK-FOR-U (1-866-475-3678).